Analytical testing will accelerate Numinus’ Research and Development capabilities and generate revenue through third-party clients VANCOUVER, BC, Nov. 29, 2021 /CNW/ – Numinus Wellness Inc. (“Numinus” or the “Company”) (TSXV: NUMI), a leader in psychedelics-focused mental healthcare, has today announced novel, proprietary methods for psychedelic mushroom compound screening. The testing…


Previous articlePsychedelic Bulletin: Microdosing Study Causes a Stir; COMPASS Secures 5th US Patent; Leave Toads Alone?
Next articleRed Light Holland Reports Second Quarter 2021 Results